Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $231.3 million.

  • Compass Therapeutics' Liabilities and Shareholders Equity rose 5505.03% to $231.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $619.8 million, marking a year-over-year decrease of 47.66%. This contributed to the annual value of $140.4 million for FY2024, which is 1050.01% down from last year.
  • Latest data reveals that Compass Therapeutics reported Liabilities and Shareholders Equity of $231.3 million as of Q3 2025, which was up 5505.03% from $116.7 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Liabilities and Shareholders Equity peaked at $231.3 million during Q3 2025, and registered a low of $116.7 million during Q2 2025.
  • In the last 3 years, Compass Therapeutics' Liabilities and Shareholders Equity had a median value of $156.9 million in 2023 and averaged $161.8 million.
  • The largest annual percentage gain for Compass Therapeutics' Liabilities and Shareholders Equity in the last 5 years was 5505.03% (2025), contrasted with its biggest fall of 2500.66% (2025).
  • Over the past 3 years, Compass Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $156.9 million in 2023, then fell by 10.5% to $140.4 million in 2024, then skyrocketed by 64.71% to $231.3 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $231.3 million for Q3 2025, versus $116.7 million for Q2 2025 and $131.5 million for Q1 2025.